Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use

GlaxoSmithKline6,896 enrolled

Overview

This retrospective study aims to assess the economic impact of early initiation of 5-alpha-reductase inhibitor (5ARI) therapy in patients with enlarged prostate (EP) receiving 5ARI and alpha-blocker (AB) combination therapy. Both the Integrated Health Care Information Solutions and PharMetrics databases will be utilized for this study (2000-2007).

Study Type

OBSERVATIONAL

Enrollment

6,896

Conditions

Prostatic Hyperplasia

Interventions

5ARI + ABDRUG

5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin

Eligibility

Sex: MALEMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male patients aged 50 years or older * a medical claim of EP * a prescription claim for a 5ARI and AB (provided both are within 180 days of index date) * continuously eligible for 6 months prior to and at least 12 months after index prescription date. Exclusion Criteria: * diagnosis of prostate or bladder cancer * any prostate-related surgical procedure within 5 months of index date * prescription claim for finasteride indicative of male pattern baldness * 5ARI therapy initiated prior to initiating AB therapy

Outcomes

Primary Outcomes

Number of Participants With Clinical Progression

Clinical progression was identified as the occurrence of acute urinary retention and/or surgery as identified by relevant Common Procedure Terminology (CPT) procedure codes and International Classification of Diseases (ICD)-9CM diagnosis codes.